GUIDED THERAPEUTICS INC
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
GTHPStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Exhibit Number | Exhibit Description |
| 3.1 | Restated Certificate of Incorporation, as amended through November 3, 2016 (incorporated by reference to Exhibit 3.1 to the annual report on Form 10-K filed March 15, 2016) |
| 3.2 | Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed March 23, 2012) |
| 3.3 | Amended and Restated Certificate of Incorporation, (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed November 15, 2018) |
| 3.4 | Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.4 to the annual report on Form 10-K, filed April 20, 2020) |
| 3.5 | Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.5 to the annual report on Form 10-K filed April 5, 2021) |
| 3.6 | Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock (incorporated by reference to Exhibit 3.6 to the annual report on Form 10-K filed April 5, 2021) |
| 3.7 | Certificate of Designation of Preferences, Rights and Limitations of Series F-2 Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on June 10, 2021) |
| 3.8 | Certificate of Designation of Preferences, Rights and Limitations of Series G Convertible Preferred Stock (incorporated by reference to Exhibit 3.8 to the annual report on Form 10-K filed March 30, 2022) |
| 3.9 | Certificate of Amendment to the Certificate of Incorporation of Guided Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed on January 7, 2022) |
| 10.1* | Exchange Agreement dated August 27, 2025, by and between the Company and Mark Faupel |
| 10.2* | Exchange Agreement dated August 27, 2025, by and between the Company and Alan Grujic |
| 10.3* | Form of Securities Purchase Agreement dated August 29, 2025, by and among the Company and the investors named therein. |
| 10.4* | Form of Warrant Agreement Dated August 29, 2025, by and among the Company and the investors named therein. |
| 10.5* | Convertible Promissory Note, dated September 25, 2025, issued by the Company to John Imhoff in the principal amount of $160,000. |
| 10.6* | Promissory Note, dated August 27, 2025, issued by the Company to Labrys Fund II, L.P., in the principal amount of $107,800. |
| 10.7* | Securities Purchase Agreement dated August 27, 2025, by and among the Company and Labrys Fund II, L.P. |
| 10.8* | Promissory Note, dated October 3, 2025, issued by the Company to 1800 Diagional Lending LLC, in the principal amount of $123,050. |
| 10.9* | Securities Purchase Agreement dated October 3, 2025, by and among the Company and 1800 Diagional Lending, LLC. |
| 31* | Rule 13a-14(a)/15d-14(a) Certification |
| 32* | Section 1350 Certification |
| 101.1* | Interactive data files for Guided Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline XBRL: (i) the Unaudited Condensed Consolidated Balance Sheets; (ii) the Unaudited Condensed Consolidated Statements of Income; (iii) the Unaudited Condensed Consolidated Statements in Stockholders' Deficit; (iv) the Unaudited Condensed Consolidated Statements of Cash Flows; and (v) the Notes to the Unaudited Condensed Consolidated Financial Statements. |
| 104 | The cover page from Guided Therapeutics, Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (formatted in Inline XBRL and included in Exhibit 101) |
*Filed herewith
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.